Last checked at 25 Feb 2021 13:00
Hikma Pharmaceuticals PLC - EIP Awards
LONDON, 25 February 2021: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK)(LEI: 549300BNS685UXH4JI75) announces that the Remuneration Committee made the following conditional awards under the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company.
Awards under the EIP were made on 25 February 2021 at a price of 2,525 pence per Ordinary Share (being the average price for the 30-day period prior to 31 December 2020, in accordance with the EIP rules) as follows:
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Said Darwazah
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Said Darwazah |
2 | Reason for the notification | |
a) | Position/status | Executive Chairman |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 34,827 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Said Darwazah
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Said Darwazah |
2 | Reason for the notification | |
a) | Position/status | Executive Chairman |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 19,830 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Sigurdur Olafsson
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Sigurdur Olafsson |
2 | Reason for the notification | |
a) | Position/status | Chief Executive Officer |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 41,527 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Sigurdur Olafsson
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Sigurdur Olafsson |
2 | Reason for the notification | |
a) | Position/status | Chief Executive Officer |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 24,836 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Mazen Darwazah
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Mazen Darwazah |
2 | Reason for the notification | |
a) | Position/status | Executive Vice Chairman |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 24,319 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Mazen Darwazah
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Mazen Darwazah |
2 | Reason for the notification | |
a) | Position/status | Executive Vice Chairman |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 13,903 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Bassam Kanaan
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Bassam Kanaan |
2 | Reason for the notification | |
a) | Position/status | EVP, Corporate Development and M&A |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 17,307 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Bassam Kanaan
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Bassam Kanaan |
2 | Reason for the notification | |
a) | Position/status | EVP, Corporate Development and M&A |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 13,378 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Khalid Nabilsi
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Khalid Nabilsi |
2 | Reason for the notification | |
a) | Position/status | Chief Financial Officer |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 17,390 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Khalid Nabilsi
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Khalid Nabilsi |
2 | Reason for the notification | |
a) | Position/status | Chief Financial Officer |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 13,927 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Riad Mishlawi
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Riad Mishlawi |
2 | Reason for the notification | |
a) | Position/status | President, Injectables |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 20,285 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Riad Mishlawi
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Riad Mishlawi |
2 | Reason for the notification | |
a) | Position/status | President, Injectables |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 17,120 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Majda Labadi
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Majda Labadi |
2 | Reason for the notification | |
a) | Position/status | EVP, Organisational Development |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 11,205 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Majda Labadi
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Majda Labadi |
2 | Reason for the notification | |
a) | Position/status | EVP, Organisational Development |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 8,662 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Susan Ringdal
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Susan Ringdal |
2 | Reason for the notification | |
a) | Position/status | EVP, Strategic Planning and Global Affairs |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 8,813 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Susan Ringdal
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Susan Ringdal |
2 | Reason for the notification | |
a) | Position/status | EVP, Strategic Planning and Global Affairs |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 6,812 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Brian Hoffmann
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Brian Hoffmann |
2 | Reason for the notification | |
a) | Position/status | President, US Generics |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 12,119 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Brian Hoffmann
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Brian Hoffmann |
2 | Reason for the notification | |
a) | Position/status | President, US Generics |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 10,227 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Henriette Nielsen
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Henriette Nielsen |
2 | Reason for the notification | |
a) | Position/status | EVP, Business Operations |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 14,374 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Henriette Nielsen
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Henriette Nielsen |
2 | Reason for the notification | |
a) | Position/status | EVP, Business Operations |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 12,130 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Shahin Fesharaki
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Shahin Fesharaki |
2 | Reason for the notification | |
a) | Position/status | Chief Scientific Officer |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 14,972 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Shahin Fesharaki
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Shahin Fesharaki |
2 | Reason for the notification | |
a) | Position/status | Chief Scientific Officer |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 11,574 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Hussein Arkhagha
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Hussein Arkhagha |
2 | Reason for the notification | |
a) | Position/status | Chief Counsel |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 7,867 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Hussein Arkhagha
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Hussein Arkhagha |
2 | Reason for the notification | |
a) | Position/status | Chief Counsel |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years. |
c) | Price(s) and volume(s) | Price(s): £25.25 Volume(s): 5,245 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 25 February 2021 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Peter SpeirsCompany Secretary, responsible for releasing this announcement+44 (0) 20 7399 2760